Financial Performance - The company's operating revenue for the first half of 2024 was approximately ¥1.44 billion, a decrease of 5.82% compared to ¥1.53 billion in the same period last year[12]. - Net profit attributable to shareholders for the first half of 2024 was approximately ¥179.77 million, an increase of 6.99% from ¥168.03 million in the previous year[12]. - The net cash flow from operating activities increased by 34.31%, reaching approximately ¥342.14 million compared to ¥254.74 million in the same period last year[12]. - Basic earnings per share for the first half of 2024 were ¥0.2472, representing an increase of 13.29% from ¥0.2182 in the same period last year[13]. - The weighted average return on net assets for the first half of 2024 was 6.16%, an increase of 0.65 percentage points compared to 5.51% in the previous year[13]. - The company reported a net profit excluding non-recurring gains and losses of approximately ¥162.42 million, a slight increase of 2.09% from ¥159.10 million in the previous year[12]. - The company achieved a revenue of 1.444 billion yuan, a year-on-year decrease of 5.82%[22]. - The net profit attributable to shareholders was 180 million yuan, representing a year-on-year increase of 6.99%[22]. - The company reported a total revenue of CNY 721,788,574.18 from operating activities, slightly down from CNY 729,715,917.44 in the same period last year[79]. Assets and Liabilities - The total assets as of June 30, 2024, were approximately ¥3.75 billion, a decrease of 2.59% from ¥3.85 billion at the end of the previous year[12]. - The net assets attributable to shareholders decreased by 3.36%, amounting to approximately ¥2.88 billion compared to ¥2.98 billion at the end of the previous year[12]. - The company's total liabilities decreased to CNY 2,993,305,890.00 from CNY 3,000,000,000.00 in the previous year, indicating a slight improvement in financial health[82]. - The company's total equity was CNY 3,099,166,508.22, a slight decrease from CNY 3,125,501,731.93 in the previous year[69]. - The total liabilities increased from ¥860,330,813.75 to ¥865,120,475.30, an increase of about 0.9%[66]. Industry Trends - The pharmaceutical manufacturing industry in China experienced a revenue decline of 1.0% year-on-year, with total revenue reaching 1,003.71 billion RMB from January to May 2024[16]. - The total profit of the pharmaceutical manufacturing industry grew by 0.3% year-on-year, amounting to 140.99 billion RMB during the same period[16]. - The pharmaceutical industry is entering a new cycle of significant restructuring and integration due to ongoing medical anti-corruption efforts and international geopolitical uncertainties[16]. Research and Development - The company is focusing on the development of pediatric traditional Chinese medicine, supported by new national policies encouraging research and production in this area[16]. - The company aims to enhance the quality and efficiency of traditional Chinese medicine through innovative extraction and quality control technologies[16]. - The company plans to enhance its R&D capabilities in pediatric drugs, leveraging policy incentives to accelerate the development of innovative drugs[17]. - R&D expenses increased by 33.02% to CNY 68.9 million due to changes in the timing of capitalizing R&D expenses and increased outsourcing[28]. - The company made significant progress in innovative drug development, with the SY005 project completing Phase IIa clinical trials and the SY009 project completing Phase II trials and submitting IND documentation for a new indication[25]. Environmental Compliance - The company implemented standardized environmental management practices, aligning with safety standards for hazardous chemicals in Shanxi Province[24]. - The company has established a wastewater treatment plant with a daily processing capacity of 1,000 tons, achieving compliance with the GB21905-2008 standard for pharmaceutical wastewater discharge[45]. - The company’s emissions of non-methane total hydrocarbons were recorded at 29.75 mg/m³, well below the standard limit of 60 mg/m³[44]. - The company has implemented a continuous monitoring system for wastewater discharge, ensuring real-time compliance with environmental standards[48]. Shareholder Information - The company repurchased a total of 49,999,929 shares, accounting for 6.49% of the total share capital[57]. - As of the end of the reporting period, the total number of ordinary shareholders was 53,625[57]. - The largest shareholder, Shanxi Yaobao Investment Group Co., Ltd., held 94,300,000 shares, representing 13.10% of the total shares[57]. Financial Management - The company has not disclosed any plans for profit distribution or capital increase during the reporting period[2]. - There were no significant risks that materially affected the company's operations during the reporting period[2]. - The company has not proposed any profit distribution or capital reserve transfer plans for the first half of 2024[40]. - The annual shareholder meeting approved all proposed resolutions without any rejections, indicating strong governance and shareholder support[38]. Accounting Policies - The company adheres to the accounting standards set by the Ministry of Finance and the disclosure rules established by the China Securities Regulatory Commission[100]. - The financial statements are prepared based on the going concern assumption and comply with the enterprise accounting standards, reflecting the company's financial position as of June 30, 2024[103]. - Significant accounting policies include a provision for bad debts for accounts receivable over RMB 10 million and exceeding 5% of the accounts receivable balance[103]. Credit Risk Management - The company assesses expected credit losses based on the weighted average of credit losses of financial instruments, considering past events, current conditions, and forecasts of future economic conditions[119]. - The provision for bad debts amounted to CNY 26,636,257.76, which is 5.9% of the total accounts receivable[175]. - The company has categorized accounts receivable into different aging brackets, with CNY 268,667,908.62 classified as receivables from distributors, representing 59.58% of the total[175]. Inventory Management - The total inventory at the end of the period is CNY 434,394,381.69, with a decrease of CNY 25,381,487.05 compared to the previous period[196]. - Raw materials inventory decreased to CNY 911,306.29, down from CNY 1,945,567.52 at the beginning of the period, reflecting a reduction of approximately 53%[197]. - Finished goods inventory increased to CNY 26,743,528.32, up from CNY 22,041,979.64, representing an increase of approximately 21%[197].

证券代码：600351 证券简称：亚宝药业 公告编号：2024-036 ●回购期限：自公司股东大会审议通过回购方案之日起不超过 6 个月。 ●回购价格：不超过人民币6.95元/股（含）（不高于董事会通过回购股份 决议前30个交易日公司股票交易均价的150%）。 ●回购资金来源：公司自有资金。 ●相关股东是否存在减持计划：除公司控股股东外，公司不存在持股5%以上 的股东。经问询，截止本公告日，公司控股股东、实际控制人不存在未来3个月、 未来6个月减持公司股票的计划。 相关风险提示： 亚宝药业集团股份有限公司 关于以集中竞价交易方式回购股份方案公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●回购用途：本次回购股份将依法全部予以注销并减少公司注册资本。 ●回购资金总额：不低于人民币 1 亿元（含）且不超过人民币 1.5 亿元（含）， 具体回购资金总额以回购期满时实际回购股份使用的资金总额为准。 1、本方案尚需提交公司股东大会以特别决议审议通过，如果股东大会未能 审议通过本方案，将导致本回购计划无法实施； 2、 ...

证券代码：600351 证券简称：亚宝药业 公告编号：2024-034 亚宝药业集团股份有限公司 关于获得药品补充申请批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，亚宝药业集团股份有限公司（以下简称"公司"）收到了国家药品监 督管理局（以下简称"国家药监局"）核准签发的关于硝苯地平缓释片（I）的 《药品补充申请批准通知书》（通知书编号：2024B03619），该药品通过仿制药质 量和疗效一致性评价。现将相关情况公告如下： 一、药品的基本情况 地址：山西省运城市芮城县富民路 43 号 7、生产企业：亚宝药业集团股份有限公司 9、审批结论：根据《中华人民共和国药品管理法》《国务院关于改革药品医 疗器械审评审批制度的意见》（国发〔2015〕44 号）和《关于仿制药质量和疗效 一致性评价工作有关事项的公告》（2017 年第 100 号）的规定，经审查，本品通 过仿制药质量和疗效一致性评价。药品有效期 18 个月。本品拟定生产批量为 360 万片，今后的商业化生产如需放大批量，请注意开展相应的放大研究及验证。 ...

证券代码：600351 证券简称：亚宝药业 公告编号：2024-033 亚宝药业集团股份有限公司 关于取得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，亚宝药业集团股份有限公司（以下简称"公司"）收到了国家药品监 督管理局（以下简称"国家药监局"）核准签发的硝苯地平控释片《药品注册证 书》（证书编号：2024S01865）。现将相关情况公告如下： 一、药品注册证书主要内容 1、药品名称：硝苯地平控释片 2、剂型：片剂 3、规格：30mg 4、包装规格：10 片/板，1 板/盒 5、注册分类：化学药品 4 类 6、药品有效期：18 个月 7、药品生产企业：亚宝药业集团股份有限公司 地址：山西省风陵渡经济开发区工业大道 1 号 8、药品批准文号：国药准字 H20244594 9、审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查， 本品符合药品注册的有关要求，批准注册，发给药品注册证书。 二、药品的其他情况 硝苯地平控释片用于治疗高血压、冠心病，慢性稳定型心绞痛（劳累性心绞 痛），最早由德国 ...

地氯雷他定是一种具有选择性外周 H1 拮抗活性的三环抗组胺剂，同时也是 毒蕈碱乙酰胆碱受体各亚型的拮抗剂，用于季节性过敏性鼻炎，常年性（非季节 性）过敏性鼻炎症状的缓解，也可用于与慢性特发性荨麻疹相关的瘙痒和荨麻疹 症状性的治疗。地氯雷他定口服溶液（0.5mg/ml）由默克旗下的先灵葆雅 （Schering-Plough）公司研发，2007 年 4 月 23 日获 EMA（欧洲药品管理局）批 证券代码：600351 证券简称：亚宝药业 公告编号：2024-032 亚宝药业集团股份有限公司 关于全资子公司取得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，亚宝药业集团股份有限公司（以下简称"公司"）全资子公司亚宝药 业四川制药有限公司收到了国家药品监督管理局（以下简称"国家药监局"）核 准签发的地氯雷他定口服溶液《药品注册证书》（证书编号：2024S01804）。现将 相关情况公告如下： 一、药品注册证书主要内容 地址：四川省彭州工业开发区柏江北路 368 号 8、药品批准文号：国药准字 H202445 ...

证券代码：600351 证券简称：亚宝药业 公告编号：2024-031 亚宝药业集团股份有限公司 关于控股股东进行股票质押式回购交易的公告 一、本次股份质押的情况 | 股东 | 是否为 | 本次质押股 | 是否为限售 | 是否 | 质押起 | 质押到 | | 占其所 | 占公司 | 质押 融资 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 控股股 | | | 补充 | | | 质权人 | 持股份 | 总股本 | | | 名称 | | 数 | 股 | | 始日 | 期日 | | | | 资金 | | | 东 | | | 质押 | | | | 比例 | 比例 | | | | | | | | | | | | | 用途 | | | | | | | | | 山西证券 | | | 补充 | | 亚宝 | 是 | 13,650,000 | 否 | 否 | 2024年6 | 2025年6 | 股份有限 | 14.48% | 1.90% | 企业 | | 投资 | | | | | 月7日 | 月6日 | | | | 流动 | ...

证券代码：600351 证券简称：亚宝药业 公告编号：2024-030 亚宝药业集团股份有限公司 关于控股股东部分股份解除质押的公告 ●截止本公告日，亚宝药业集团股份有限公司（以下简称"公司"）控股股 东山西亚宝投资集团有限公司（以下简称"亚宝投资"）持有公司股份 94,300,000股，占公司总股本的13.10%；本次质押解除后，亚宝投资所持有的公 司股份累计质押数量为17,500,000股，占其所持有公司股份总数的18.56%，占公 司总股本的2.43%。 公司于2024年5月30日收到控股股东亚宝投资转发的证券质押登记解除通知 书，获悉亚宝投资质押给山西银行股份有限公司太原新建南路支行的29,500,000 股无限售流通股办理了解除质押手续，具体情况如下： 一、本次股份解除质押的情况 1、本次股份解除质押的基本情况 | 股东名称 | 亚宝投资 | | --- | --- | | 本次解除质押股份 | 29,500,000 股 | | 占其所持股份比例 | 31.28% | | 占公司总股本比例 | 4.10% | | 解除质押时间 | 2024 年 5 月 29 日 | | 持股数量 | 94,300, ...

Key Points Company and Industry Overview 1. **Company**: Yaba Pharmaceutical Co., Ltd. 2. **Event**: 2023 and Q1 2024 Earnings Briefing 3. **Date**: Not specified in the provided content 4. **Speaker**: Ren Wei, General Manager of Yaba Pharmaceutical Co., Ltd. 5. **Purpose**: To present the company's operating performance for 2023 and Q1 2024 and express gratitude to investors, partners, and stakeholders [1]. Financial Performance 1. **Revenue**: Not specified in the provided content 2. **Profit**: Not specified in the provided content 3. **Growth Rate**: Not specified in the provided content 4. **Market Share**: Not specified in the provided content 5. **Key Products**: Not specified in the provided content [1]. Future Outlook 1. **2024 Outlook**: Not specified in the provided content 2. **Industry Trends**: Not specified in the provided content 3. **Strategic Initiatives**: Not specified in the provided content 4. **Regulatory Environment**: Not specified in the provided content 5. **Competitive Landscape**: Not specified in the provided content [1]. Other Important Points 1. **Investor Relations**: Not specified in the provided content 2. **Stakeholder Engagement**: Not specified in the provided content 3. **Community Impact**: Not specified in the provided content 4. **Sustainability Efforts**: Not specified in the provided content 5. **Technology Integration**: Not specified in the provided content [1].

证券代码：600351 证券简称：亚宝药业 公告编号：2024-028 亚宝药业集团股份有限公司 重要内容提示： ●截止本公告日，亚宝药业集团股份有限公司（以下简称"公司"）控股股 东山西亚宝投资集团有限公司（以下简称"亚宝投资"）持有本公司股份 94,300,000股，占公司总股本的13.10%，亚宝投资所持有的公司股份累计质押股 份数为47,000,000股，占其持有公司股份总数的49.84%，占公司总股本的6.53%。 公司于2024年5月22日接到控股股东亚宝投资关于进行股票质押式回购交易 的通知，现将相关情况公告如下： 一、本次股份质押的情况 | 股东 | 是否为 | 本次质押股 | 是否为限售 | 是否 | 质押起 | 质押到 | | 占其所 | 占公司 | 质押 融资 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 控股股 | | | 补充 | | | 质权人 | 持股份 | 总股本 | | | 名称 | 东 | 数 | 股 | 质押 | 始日 | 期日 | | 比例 | 比例 | 资金 | | ...

关于召开 2023 年度暨 2024 年第一季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 证券代码：600351 证券简称：亚宝药业 公告编号：2024-027 亚宝药业集团股份有限公司 三、 参加人员 董事长：任武贤先生 投资者可于 2024 年 05 月 21 日(星期二) 至 05 月 27 日(星期一)16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 wangyu@yabaoyaoye.com 进行提问。公司将在说明会上对投资者普遍关注的问题 进行回答。 亚宝药业集团股份有限公司（以下简称"公司"）已于 2024 年 4 月 26 日发 布公司 2023 年年度报告和 2024 年第一季度报告，为便于广大投资者更全面深入 地了解公司 2023 年度及 2024 年第一季度经营成果、财务状况，公司计划于 2024 年 05 月 28 日上午 10:00-11:30 举行 2023 年度暨 2024 年第一季度业绩说明会， 就投资者关心的问题进行交流。 一 ...